A consortium of Austrian research groups from the University of Vienna, MedUni Vienna and Technikum Wien, together with ...
Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for prostate cancer ...
The Alzheimer’s Disease Research Center (ADRC) at the University of Pittsburgh is one of the country’s hubs for researchers ...
Through close collaboration between United Imaging and Papapostolou Healthcare Technologies, a provider of high-tech medical ...
The University of Massachusetts Lowell, Department of Chemistry, invites you to attend a Master’s Thesis defense by Madelyn Hallisey on “Novel PET Radiochemistry: Adapting Analytical and ...
A recent study provided key insights into brain degeneration in DLB, which may help clinicians better monitor this ...
Medical Device Network on MSN6d
Telix’s prostate cancer imaging agent approved in BrazilBrazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer ...
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, ...
In a study of biomarkers in Alzheimer’s dementia, plasma p-tau217 had greater agreement with CSF and amyloid-PET biomarker ...
Ladenburg, Germany, 13 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today ...
DAVID SWARTZ, Director at RadNet RDNT , reported an insider sell on March 12, according to a new SEC filing. What Happened: SWARTZ's decision to sell 25,000 shares of RadNet was revealed in a Form 4 ...
PET is a functional neuroimaging tool. In recent years, it has been used to determine the distribution of important neurotransmitters in the human brain. Compared with other functional imaging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback